Animal models in translational medicine: Validation and prediction

New Horizons in Translational Medicine

Volumn 2, Issue 1, 2014, Pages 5-11

  Denayer, Tinneke ^a   Stöhrn, Thomas ^a   Van Roy, Maarten ^a  

^a ABLYNX NV   (Belgium)

Author keywords

Animal model; Drug development; Fit for purpose validation; Translational value

Indexed keywords

CHIMERIC ANTIGEN RECEPTOR; INTERLEUKIN 2 RECEPTOR GAMMA;

ANIMAL MODEL; ARTICLE; CANCER RESEARCH; DISEASE MODEL; DRUG EFFICACY; DRUG SAFETY; EXPERIMENTAL MODEL; FACE VALIDITY; GENETICALLY ENGINEERED MOUSE STRAIN; GOVERNMENT; HUMAN; IMMUNE SYSTEM; NONHUMAN; PREDICTIVE VALIDITY; PREDICTIVE VALUE; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; REPRODUCIBILITY; SCORING SYSTEM; TRANSLATIONAL RESEARCH; TREATMENT DURATION; TUMOR XENOGRAFT; VALIDATION STUDY;

EID: 84921911047     PISSN: None     EISSN: 23075023     Source Type: Journal    
DOI: 10.1016/j.nhtm.2014.08.001     Document Type: Article

References (42)

1. S.C. Williams, Small nanobody drugs win big backing from pharma, Nat. Med. 19 (11) (2013) 1355-1356.
2. J. Arrowsmith, Trial watch: phase II failures: 2008-2010, Nat. Rev. Drug Discov. 10 (5) (2011) 328-329.
3. J. Arrowsmith, Trial watch: phase III and submission failures: 2007-2010, Nat. Rev. Drug. Discov. 10 (2) (2011) 87.
4. M.N. Bouchlaka, G.D. Sckisel, M. Chen, A. Mirsoian, A.E. Zamora, E. Maverakis, D.E. Wilkins, K.L. Alderson, H.H. Hsiao, J.M. Weiss, et al., Aging predisposes to acute inflammatory induced pathology after tumor immunotherapy, J. Exp. Med. 210 (11) (2013) 2223-2237.
5. S. Hansen, R.G. Leslie, TGN1412: scrutinizing preclinical trials of antibodybased medicines, Nature 441 (7091) (2006) 282.
6. R. Stebbings, L Findlay, C Edwards, D. Eastwood, C. Bird, D. North, Y. Mistry, P. Dilger, E. Liefooghe, I. Cludts, et al., "Cytokine storm" in the phase I trial of monoclonal antibody TGN1412: better understanding the causes to improve preclinical testing of immunotherapeutics, J. Immunol. 179 (5) (2007) 3325-3331.
7. H. Attarwala, TGN1412: from discovery to disaster, J. Young Pharm. 2 (3) (2010) 332-336.
8. J.C. Crabbe, D. Wahlsten, B.C. Dudek, Genetics of mouse behavior: interactions with laboratory environment, Science 284 (5420) (1999) 1670-1672.
9. S.H. Richter, J.P. Garner, B. Zipser, L Lewejohann, N. Sachser, C. Touma, B. Schindler, S. Chourbaji, C. Brandwein, P. Gass, et al., Effect of population heterogenization on the reproducibility of mouse behavior: a multi-laboratory study, PLoS One 6 (1) (2011) e16461.
10. D. Wahlsten, P. Metten, T.J. Phillips, S.L. Boehm 2nd, S. Burkhart-Kasch, J. Dorow, S. Doerksen, C. Downing, J. Fogarty, K. Rodd-Henricks, et al., Different data from different labs: lessons from studies of gene-environment interaction, J. Neurobiol. 54 (1) (2003) 283-311.
11. C.R. Hooijmans, R. de Vries, M. Leenaars, J. Curfs, M. Ritskes-Hoitinga, Improving planning, design, reporting and scientific quality of animal experiments by using the Gold Standard Publication Checklist, in addition to the ARRIVE guidelines, Br. J. Pharmacol. 162 (6) (2011) 1259-1260.
12. C. Kilkenny, W.J. Browne, I.C. Cuthill, M. Emerson, D.G. Altman, Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research, PLoS Biol. 8 (6) (2010) e1000412.
13. C. Kilkenny, W.J. Browne, I.C. Cuthill, M. Emerson, D.G. Altman, Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research, Osteoarthr. Cartil. 20 (4) (2012) 256-260.
14. A.S. Rice, D. Cimino-Brown, J.C. Eisenach, V.K. Kontinen, M.L Lacroix-Fralish, I. Machin, J.S. Mogil, T. Stohr, Animal models and the prediction of efficacy in clinical trials of analgesic drugs: a critical appraisal and call for uniform reporting standards, Pain 139 (2) (2008) 243-247.
15. Y Lamberty, D.G. Margineanu, H. Klitgaard, Absence of negative impact of levetiracetam on cognitive function and memory in normal and amygdalakindled rats, Epilepsy Behav. 1 (5) (2000) 333-342.
16. C. Weyer, J.F. Gautier, E. Danforth Jr, Development of beta 3-adrenoceptor agonists for the treatment of obesity and diabetes - an update, Diabetes Metab. 25 (1) (1999) 11-21.
17. F. Sams-Dodd, Strategies to optimize the validity of disease models in the drug discovery process, Drug Discov. Today 11 (7-8) (2006) 355-363.
18. RJ. Derscheid, M.R. Ackermann, Perinatal lamb model of respiratory syncytial virus (RSV) infection, Viruses 4 (10) (2012) 2359-2378.
19. R. Villenave, S. Thavagnanam, S. Sarlang, J. Parker, I. Douglas, G. Skibinski, L G. Heaney, J.P. McKaigue, P.V. Coyle, M.D. Shields, et al., In vitro modeling of respiratory syncytial virus infection of pediatric bronchial epithelium, the primary target of infection in vivo, Proc. Natl. Acad. Sci. USA 109 (13) (2012) 5040-5045.
20. R. Ito, T. Takahashi, I. Katano, M. Ito, Current advances in humanized mouse models, Cell. Mol. Immunol. 9 (3) (2012) 208-214.
21. D. Siolas, G.J. Hannon, Patient-derived tumor xenografts: transforming clinical samples into mouse models, Cancer Res. 73 (17) (2013) 5315-5319.
22. T.M. Pitts, A.C. Tan, G.N. Kulikowski, J.J. Tentler, A.M. Brown, S.A. Flanigan, S. Leong, CD. Coldren, F.R. Hirsch, M. Varella-Garcia, et al., Development of an integrated genomic classifier for a novel agent in colorectal cancer: approach to individualized therapy in early development, Clin. Cancer Res. 16 (12) (2010) 3193-3204.
23. J.J. Tentler, A.C. Tan, CD. Weekes, A. Jimeno, S. Leong, T.M. Pitts, J.J. Arcaroli, W.A. Messersmith, S.G. Eckhardt, Patient-derived tumour xenografts as models for oncology drug development, Nat. Rev. Clin. Oncol. 9 (6) (2012) 338-350.
24. H.H. Fiebig, A. Maier, A.M. Burger, Clonogenic assay with established human tumour xenografts: correlation of in vitro to in vivo activity as a basis for anticancer drug discovery, Eur. J. Cancer 40 (6) (2004) 802-820.
25. R.S. Kerbel, Human tumor xenografts as predictive preclinical models for anticancer drug activity in humans: better than commonly perceived-but they can be improved, Cancer Biol. Ther. 2 (4 Suppl. 1) (2003) S134-S139.
26. M. Hidalgo, E. Bruckheimer, N.V. Rajeshkumar, I. Garrido-Laguna, E. De Oliveira, B. Rubio-Viqueira, S. Strawn, M.J. Wick, J. Martell, D. Sidransky, A pilot clinical study of treatment guided by personalized tumorgrafts in patients with advanced cancer, Mol. Cancer Ther. 10 (8) (2011) 1311-1316.
27. S.J. Weroha, M.A. Becker, S. Enderica-Gonzalez, S.C Harrington, A.L. Oberg, M. J. Maurer, S.E. Perkins, M. Alhilli, K.A. Butler, S. McKinstry, et al., Tumorgrafts as in vivo surrogates for women with ovarian cancer, Clin. Cancer Res. 20 (5) (2014) 1288-1297.
28. L.D. Shultz, M.A. Brehm, J.V. Garcia-Martinez, D.L Greiner, Humanized mice for immune system investigation: progress, promise and challenges, Nat. Rev. Immunol. 12 (11) (2012) 786-798.
29. Q. Zhou, J. Facciponte, M. Jin, Q. Shen, Q. Lin, Humanized NOD-SCID IL2rg(-/-) mice as a preclinical model for cancer research and its potential use for individualized cancer therapies, Cancer Lett. 344 (1) (2014) 13-19.
30. R. Danner, S.N. Chaudhari, J. Rosenberger, J. Surls, T.L. Richie, T.D. Brumeanu, S. Casares, Expression of HLA class II molecules in humanized NOD. Rag1KO. IL2RgcKO mice is critical for development and function of human T and B cells, PLoS One 6 (5) (2011) e19826
31. L.D. Shultz, Y. Saito, Y. Najima, S. Tanaka, T. Ochi, M. Tomizawa, T. Doi, A. Sone, N. Suzuki, H. Fujiwara, et al., Generation of functional human T-cell subsets with HLA-restricted immune responses in HLA class I expressing NOD/SCID/IL2r gamma(null) humanized mice, Proc. Natl. Acad. Sci. USA 107 (29) (2010) 13022-13027.
32. M. Singh, P. Singh, D. Vaira, M. Amand, S. Rahmouni, M. Moutschen, Minocycline attenuates HIV-1 infection and suppresses chronic immune activation in humanized NOD/LtsZ-scidIL-2Rgamma mice, Immunology 142 (4) (2014) 562-572.
33. D. Abate-Daga, K.H. Lagisetty, E. Tran, Z. Zheng, L. Gattinoni, Z. Yu, W.R. Burns, A.M. Miermont, Y. Teper, U. Rudloff, et al., A novel chimeric antigen receptor against prostate stem cell antigen mediates tumor destruction in a humanized mouse model of pancreatic cancer, Hum. Gene Ther. (2014), 10.1089/hum. 2013.209, in press.
34. D.C. Brown, R. Boston, J.C. Coyne, J.T. Farrar, A novel approach to the use of animals in studies of pain: validation of the canine brief pain inventory in canine bone cancer, Pain Med. 10 (1) (2009) 133-142.
35. P.C. Guest, M.G. Gottschalk, S. Bahn, Proteomics: improving biomarker translation to modern medicine? Genome Med. 5 (2) (2013) 17.
36. L. Arendt-Nielsen, M. Curatolo, A. Drewes, Human experimental pain models in drug development: translational pain research, Curr. Opin. Investig. Drugs 8 (1) (2007) 41-53.
37. A.E. Olesen, T. Andresen, C. Staahl, A.M. Drewes, Human experimental pain models for assessing the therapeutic efficacy of analgesic drugs, Pharmacol. Rev. 64 (3) (2012) 722-779.
38. G. Maxwell, C. Mackay, Application of a systems biology approach to skin allergy risk assessment, Altern. Lab. Anim. 36 (5) (2008) 521-556.
39. B.J. Schmidt, J.A. Papin, C.J. Musante, Mechanistic systems modeling to guide drug discovery and development, Drug Discov. Today 18 (3-4) (2013) 116-127.
40. H. Geerts, A. Spiros, P. Roberts, R. Carr, Quantitative systems pharmacology as an extension of PK/PD modeling in CNS research and development, J. Pharmacokinet. Pharmacodyn. 40 (3) (2013) 257-265.
41. P.A. Konstantinopoulos, U.A. Matulonis, Current status and evolution of preclinical drug development models of epithelial ovarian cancer, Front. Oncol. 3 (2013) 296.
42. M. Moro, G. Bertolini, M. Tortoreto, U. Pastorino, G. Sozzi, L. Roz, Patientderived xenografts of non small cell lung cancer: resurgence of an old model for investigation of modern concepts of tailored therapy and cancer stem cells, J. Biomed. Biotechnol. 2012 (2012) 568567.